Undergraduate Journal of Global Citizenship



In the wake of the Covid-19 pandemic, unequal vaccine access has exposed the inequities perpetuated by the transnational industry that is corporate pharmaceuticals. Intellectual property rights catalyze the lack of production in low-income countries, leading to disproportionate vaccination rates in the global north. Yet lobbyists argue that intellectual property rights foster innovation of new drugs by billion-dollar pharma companies. A deep dive into access, pharmaceutical activity, profit margins, and IP law reveal some possible solutions to the access problem.



To view the content in your browser, please download Adobe Reader or, alternately,
you may Download the file to your hard drive.

NOTE: The latest versions of Adobe Reader do not support viewing PDF files within Firefox on Mac OS and if you are using a modern (Intel) Mac, there is no official plugin for viewing PDF files within the browser window.